SCHEMBL1203496

SCHEMBL1203496

O=C(Nc1ccccc1)c1cnc2ccc(N3CCc4ccccc4C3)nn12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN11 Q06124 1/20 0.53
▸ GRIN2D O15399 7/20 0.47
▸ GRIN3B O60391 7/20 0.47
▸ GRIN1 Q05586 7/20 0.47
▸ GRIN2A Q12879 7/20 0.47
▸ GRIN2B Q13224 7/20 0.47
▸ GRIN2C Q14957 7/20 0.47
▸ GRIN3A Q8TCU5 7/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ ALOX15 P16050 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ KDR P35968 2/20 0.44
▸ PDGFRB P09619 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1203002 0.92 PTPN11 (0.44) PTPN11GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL3793530 0.78 PTPN11 (0.58) PTPN11GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL1203484 0.78 DDR2 (0.44) SMN1; SMN2KDM4EALDH1A1NPC1RAB9A
SCHEMBL14897368 0.74 IRAK4 (0.46) SMN1; SMN2ALDH1A1POLBMAPTNPC1
SCHEMBL14896979 0.74 IRAK4 (0.49) SMN1; SMN2ALDH1A1RAB9AIRAK4
SCHEMBL1202738 0.74 IRAK4 (0.41) SMN1; SMN2ALDH1A1POLBMAPTIRAK4
SCHEMBL1203470 0.74 KCNQ3 (0.46) SMN1; SMN2KDM4EALDH1A1POLBNPC1
SCHEMBL1202894 0.73 CYP3A4 (0.49) SMN1; SMN2ALDH1A1MAPTRAB9A
SCHEMBL1203606 0.73 FYN (0.59) —
SCHEMBL1202745 0.73 MKNK1 (0.56) KDM4EALDH1A1MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2011-02-24 — — US disclosed
EP-2217601-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2010-08-18 — — EP disclosed
WO-2009060197-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2009-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors PIM1, PIM3, PIM2 PTPN11 971/4885GRIN2D 3722/4885GRIN3B 4203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback